Home > The news of EUROGIP and occupational risks in Europe >
The European Commission has published an indicative list of dangerous medicines as part of its commitment to continuously update Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work.
Essential drugs used in the treatment of certain diseases can have adverse effects not only on patients, but also on workers exposed to them in the workplace. Classified as “dangerous” due to the presence of carcinogenic, mutagenic or reprotoxic substances, these medicines have been listed and classified by the European Commission on the basis of data from the ECHA (European Chemicals Agency) and the EMA (European Medicines Agency).
The main aim of this list is to improve occupational risk assessment, in line with Directive 89/391/EEC, which aims to ensure the safety and health of workers at work. It also complements the technical information contained in the guidelines for the safe management of hazardous medicinal products in the workplace, published by the European Commission in April 2023.
